Kangwei (Guangzhou) Biotechnology Co., Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kangwei (Guangzhou) Biotechnology Co., Ltd - overview
Established
2018
Location
Guangzhou, Guangdong, China
Primary Industry
Biotechnology
About
Based in Guangzhou, China, and founded in 2018, Kangwei (Guangzhou) Biotechnology Co. , Ltd operates as a manufacturer of anti-tumor drugs, focusing on providing cancer treatment drugs for patients. Its founding team has completed the research and development and FDA application of more than 50 new drugs, and clinical development of 40 new drugs. The company has established three technology platforms and a pipeline of new anti-tumor drugs, including immunotherapy platform, small molecule and coupling platform, and antibody drug coupling (ADC) platform.
Its immunotherapy platform includes 2 clinical trial stage drugs, CAN1012 and DPV-001, which are therapeutic oncology vaccines.
Current Investors
CAS Investment Management, Milestep capital management(Hengqin), China Capital Management
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Verticals
Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.